Novel antibacterial agents for the treatment of serious Gram-positive infections

被引:105
作者
Abbanat, D [1 ]
Macielag, M [1 ]
Bush, K [1 ]
机构
[1] Johnson & Johnson Res & Dev, Raritan, NJ 08869 USA
关键词
antiMRSA; beta-lactam; BAL9141; cephalosporin; cethromycin; dalbavancin; daptomycin; garenoxacin; gemifloxacin; glycopeptide; glycylcycline; ketolide; MRSA; oritavancin; oxazolidinone; PRSP; RWJ-54428; sitafloxacin; telithromycin; tigecycline; VRE;
D O I
10.1517/eoid.12.3.379.21491
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
With the continuing development of clinical drug resistance among bacteria and the advent of resistance to the recently released agents quinupristin-dalfopristin and linezolid, the need for new, effective agents to treat multidrug-resistant Gram-positive infections remains important. This review focuses on agents presently in clinical development for the treatment of serious multidrug-resistant staphylococcal, enterococcal and pneumococcal infections, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and penicillin-resistant Streptococcus pneumoniae. Agents to be discussed that affect the prokaryotic cell wall include the antimethicillin-resistant S. aureus cephalosporins BAL9141 and RWJ-54428, the glycopeptides oritavancin and dalbavancin and the lipopeptide daptomycin. Topoisomerase inhibitors include the fluoroquinolones gemifloxacin, sitafloxacin and garenoxacin. Protein synthesis inhibitors are represented by the ketolides telithromycin and cethromycin, the oxazolidinones and the glycylcycline tigecycline. Although each of these compounds has demonstrated antibacterial activity against antibiotic-resistant pathogens, their final regulatory approval will depend on an acceptable clinical safety profile.
引用
收藏
页码:379 / 399
页数:21
相关论文
共 139 条
  • [11] Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection
    Berry, V
    Page, R
    Satterfield, J
    Singley, C
    Straub, R
    Woodnutt, G
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 : 79 - 85
  • [12] BIRD N, 2000, 40 INT C ANT AG CHEM, P477
  • [13] BLAIS J, 2000, 40 INT C ANT AG CHEM, P196
  • [14] The macrolides
    Blondeau, JM
    DeCarolis, E
    Metzler, KL
    Hansen, GT
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (02) : 189 - 215
  • [15] THE ACTIVITY OF DAPTOMYCIN ON ENTEROCOCCUS-FAECIUM PROTOPLASTS - INDIRECT EVIDENCE SUPPORTING A NOVEL MODE OF ACTION ON LIPOTEICHOIC ACID SYNTHESIS
    BOARETTI, M
    CANEPARI, P
    LLEO, MD
    SATTA, G
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (02) : 227 - 235
  • [16] In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic
    Candiani, G
    Abbondi, M
    Borgonovi, M
    Romanò, G
    Parenti, F
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) : 179 - 192
  • [17] CANDIANI GP, 2001, 41 INT C ANT AG CHEM, P54
  • [18] In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria
    Chamberland, S
    Blais, J
    Hoang, M
    Dinh, C
    Cotter, D
    Bond, E
    Gannon, C
    Park, C
    Malouin, F
    Dudley, MN
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (05) : 1422 - 1430
  • [19] Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics
    Champney, WS
    Tober, CL
    [J]. CURRENT MICROBIOLOGY, 1998, 37 (06) : 418 - 425
  • [20] CHAMPNEY WS, 1999, RRD ANTIMICROB AG 1, V3, P39